New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 25, 2014
16:17 EDTWDC, AMGNWestern Digital CFO Leyden to retire, Olivier Leonetti to succeed
Western Digital (WDC) announced that CFO Tim Leyden is retiring. He is being succeeded by Olivier Leonetti, who has served as vice president, finance at Amgen (AMGN) from 2011. Leyden will remain with the company through January 2015 in a transition role and advisory capacity to president and chief executive officer Steve Milligan and to Leonetti for an interim period to ensure a smooth transition. The changes are effective as of September 8.
News For WDC;AMGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
January 28, 2015
07:54 EDTWDCWestern Digital margin, market share loss concerns overblown, says Susquehanna
Subscribe for More Information
January 27, 2015
18:46 EDTWDCWestern Digital says no plans to change current capital allocation
Subscribe for More Information
18:20 EDTWDCOn The Fly: After Hours Movers
UP AFTER EARNINGS: ABIOMED (ABMD), up 27%... Yahoo (YHOO), up 7.2% after reporting fourth quarter results and that it is planning a tax-free spin-off of remaining Alibaba (BABA) stake... Freescale Semiconductor (FSL), up 10%... Marten Transport (MRTN), up 6%... U.S. Steel (X), up 9.2%... Key Tronic (KTCC), up 4%... Juniper Networks (JNPR), up 4.4%... Western Digital (WDC), consensus 2.6%... Electronic Arts (EA), up 4.8%... VMware (VMW), up 1.7%... AT&T (T), up 1.9%... Apple (AAPL), up 5.1%. ALSO HIGHER: Cirrus Logic (CRUS), up 2.9%, Skyworks (SWKS), up 1.3%, NXP Semiconductors (NXPI), up 1.5%, and Qorvo (QRVO), up 1% following Apple's first quarter results... EMC (EMC), up 2.1% following VMware's fourth quarter results... Alibaba (BABA), up marginally following Yahoo results and tax-free spin-off plans... DOWN AFTER EARNINGS: Ethan Allen (ETH), down 13.1%... EZCORP (EZPW), down 7.1%... International Game Technology (IGT), down 2.9%... Open Text (OTEX), down 4.4%. ALSO LOWER: Synergy Resources (SYRG), down 3.7% after filing to sell $150M of common stock.
18:17 EDTWDCWestern Digital sees Q3 adjusted EPS $1.90-$2.00, consensus $1.99
Subscribe for More Information
18:11 EDTWDCWestern Digital reports Q2 adjusted gross margin 30.5%
Comment from company's Q2 earnings conference call.
17:00 EDTAMGNAmgen Q4 Enbrel sales grew 19% quarter over quarter
Subscribe for More Information
16:18 EDTWDCWestern Digital generates $243M in cash from operations in Q2
Subscribe for More Information
16:18 EDTWDCWestern Digital repuchased 3.2M shares during Q2
Subscribe for More Information
16:16 EDTWDCWestern Digital reports Q2 adjusted EPS $2.26, consensus $2.10
Subscribe for More Information
16:15 EDTAMGNAmgen submits applications in US and Europe for Kyprolis
Amgen and its subsidiary Onyx Pharmaceuticals announced the submission of a supplemental New Drug Application,sNDA to the U.S. Food and Drug Administration and a Marketing Authorization Application to the European Medicines Agency for Kyprolis for Injection to seek approval for the treatment of patients with relapsed multiple myeloma who have received at least one prior therapy. In the U.S., the sNDA is designed to support the conversion of accelerated approval to full approval and expand the current approved indication. In the European Union, Kyprolis received orphan drug designation and the MAA has been granted accelerated assessment. The sNDA and MAA are based on data from the Phase 3 ASPIRE (CArfilzomib, Lenalidomide, and DexamethaSone versus Lenalidomide and Dexamethasone for the treatment of PatIents with Relapsed Multiple MyEloma) trial and other relevant data. "Multiple myeloma is an incurable blood cancer that often becomes resistant to treatment, underscoring the need for new therapeutic options that provide deep and durable responses to extend the time patients live without their disease progressing," said Pablo J. Cagnoni, M.D., president, Onyx Pharmaceuticals, Inc. "The U.S. and EU submissions support our goal of bringing Kyprolis to patients with relapsed multiple myeloma."
16:06 EDTAMGNAmgen trades higher after hours, levels to watch
Subscribe for More Information
16:04 EDTAMGNAmgen backs FY15 EPS view $9.05-$9.40, consensus $9.29
Backs FY15 revenue view $20.8B-$21.3B, consensus $20.87B.
16:03 EDTAMGNAmgen reports Q4 EPS $2.16, consensus $2.05
Subscribe for More Information
15:35 EDTAMGN, WDCNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Apple (AAPL), consensus $2.60; AT&T (T), consensus 55c; Amgen (AMGN), consensus $2.05; Yahoo (YHOO), consensus 29c; ACE (ACE), consensus $2.29; Stryker (SYK), consensus $1.45; Western Digital (WDC), consensus $2.10; Electronic Arts (EA), consensus 92c; Juniper (JNPR), consensus 31c; Total System Services (TSS), consensus 53c; Freescale Semiconductor (FSL), consensus 33c; Amdocs (DOX), consensus 81c; VMware (VMW), consensus $1.07; International Game Technology (IGT), consensus 25c; United States Steel (X), consensus 87c; Cytec (CYT), consensus 61c.
14:41 EDTWDCWestern Digital technical notes ahead of earnings
Subscribe for More Information
12:57 EDTAMGNEarnings Preview: Amgen's Kyprolis, Prolia sales key for Q4 results
Subscribe for More Information
06:26 EDTWDCSeagate likely lost share to Western Digital, says Citigroup
Subscribe for More Information
January 26, 2015
11:18 EDTWDCSeagate, Western Digital pullback a buying opportunity, says Brean Capital
Subscribe for More Information
January 22, 2015
07:56 EDTWDCBullish stance continues for Western Digital, Seagate, says Brean Capital
Brean Capital said it maintains its bullish stance on hard disk-drive makers Western Digital (WDC) and Seagate (STX), citing continued growth, margin expansion and ongoing multiple expansion. Brean Capital reiterates its Buy rating on both Western Digital and Seagate shares.
January 21, 2015
10:16 EDTAMGNLeerink biopharma analysts hold an analyst/industry conference call
Analyst Fernandez, along with Dr. Paul Gurbel and Dr. Richard Becker, discuss AstraZeneca's PEGASUS trial and the current use of Brilinta and dual antiplatelet therapy for prevention of CV disease and implications of the recently completed DAPT trial on an Analyst/Industry conference call to be held on January 21 at 1:30 pm.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use